182 related articles for article (PubMed ID: 22669447)
1. Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion.
Ur-Rehman T; Slepenkin A; Chu H; Blomgren A; Dahlgren MK; Zetterström CE; Peterson EM; Elofsson M; Gylfe A
J Antibiot (Tokyo); 2012 Aug; 65(8):397-404. PubMed ID: 22669447
[TBL] [Abstract][Full Text] [Related]
2. Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia.
Dahlgren MK; Zetterström CE; Gylfe S; Linusson A; Elofsson M
Bioorg Med Chem; 2010 Apr; 18(7):2686-703. PubMed ID: 20219378
[TBL] [Abstract][Full Text] [Related]
3. Dibenzocyclooctadiene lignans from Schisandra spp. selectively inhibit the growth of the intracellular bacteria Chlamydia pneumoniae and Chlamydia trachomatis.
Hakala E; Hanski L; Uvell H; Yrjönen T; Vuorela H; Elofsson M; Vuorela PM
J Antibiot (Tokyo); 2015 Oct; 68(10):609-14. PubMed ID: 25944533
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of garenoxacin against Chlamydia spp.
Donati M; Pollini GM; Sparacino M; Fortugno MT; Laghi E; Cevenini R
J Antimicrob Chemother; 2002 Sep; 50(3):407-10. PubMed ID: 12205067
[TBL] [Abstract][Full Text] [Related]
5. Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae.
Chu H; Slepenkin A; Elofsson M; Keyser P; de la Maza LM; Peterson EM
Int J Antimicrob Agents; 2010 Aug; 36(2):145-50. PubMed ID: 20605703
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Chlamydial infections: 2014 update.
Kohlhoff SA; Hammerschlag MR
Expert Opin Pharmacother; 2015 Feb; 16(2):205-12. PubMed ID: 25579069
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
Roblin PM; Hammerschlag MR
Int J Antimicrob Agents; 2000 Sep; 16(1):61-3. PubMed ID: 11185415
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
Roblin PM; Kohlhoff SA; Parker C; Hammerschlag MR
Antimicrob Agents Chemother; 2010 Mar; 54(3):1358-9. PubMed ID: 20038627
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
Kohlhoff SA; Huband MD; Hammerschlag MR
Antimicrob Agents Chemother; 2014 Dec; 58(12):7595-6. PubMed ID: 25288086
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
Kohlhoff SA; Roblin PM; Reznik T; Hawser S; Islam K; Hammerschlag MR
Antimicrob Agents Chemother; 2004 May; 48(5):1885-6. PubMed ID: 15105151
[TBL] [Abstract][Full Text] [Related]
11. Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.
Slepenkin A; Chu H; Elofsson M; Keyser P; Peterson EM
J Infect Dis; 2011 Nov; 204(9):1313-20. PubMed ID: 21933873
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.
Bailey L; Gylfe A; Sundin C; Muschiol S; Elofsson M; Nordström P; Henriques-Normark B; Lugert R; Waldenström A; Wolf-Watz H; Bergström S
FEBS Lett; 2007 Feb; 581(4):587-95. PubMed ID: 17257594
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite chlamydia.
Rahman MA; Azuma Y; Fukunaga H; Murakami T; Sugi K; Fukushi H; Miura K; Suzuki H; Shirai M
J Antimicrob Chemother; 2005 Nov; 56(5):861-8. PubMed ID: 16172105
[TBL] [Abstract][Full Text] [Related]
14. Impact of capsaicin, an active component of chili pepper, on pathogenic chlamydial growth (Chlamydia trachomatis and Chlamydia pneumoniae) in immortal human epithelial HeLa cells.
Yamakawa K; Matsuo J; Okubo T; Nakamura S; Yamaguchi H
J Infect Chemother; 2018 Feb; 24(2):130-137. PubMed ID: 29132924
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
16. Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.
Engström P; Nguyen BD; Normark J; Nilsson I; Bastidas RJ; Gylfe A; Elofsson M; Fields KA; Valdivia RH; Wolf-Watz H; Bergström S
J Bacteriol; 2013 Sep; 195(18):4221-30. PubMed ID: 23852872
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation.
Hanski L; Genina N; Uvell H; Malinovskaja K; Gylfe Å; Laaksonen T; Kolakovic R; Mäkilä E; Salonen J; Hirvonen J; Elofsson M; Sandler N; Vuorela PM
PLoS One; 2014; 9(12):e115115. PubMed ID: 25514140
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibitory effects of tea polyphenols on the proliferation of Chlamydia trachomatis and Chlamydia pneumoniae.
Yamazaki T; Inoue M; Sasaki N; Hagiwara T; Kishimoto T; Shiga S; Ogawa M; Hara Y; Matsumoto T
Jpn J Infect Dis; 2003 Aug; 56(4):143-5. PubMed ID: 14583635
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae by ozone.
Yamazaki T; Inoue M; Ogawa M; Shiga S; Kishimoto T; Hagiwara T; Matsumoto T; Hayashi T
Lett Appl Microbiol; 2004; 38(5):406-9. PubMed ID: 15059212
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tRNA Synthetases Induces Persistence in
Hatch ND; Ouellette SP
Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31964747
[No Abstract] [Full Text] [Related]
[Next] [New Search]
